A Minimal PBPK/PD Model with Expansion-Enhanced Target-Mediated Drug Disposition to Support a First-in-Human Clinical Study Design for a FLT3L-Fc Molecule

• Main Authors: Iraj Hosseini (Author), Brett Fleisher (Author), Jennifer Getz (Author), Jérémie Decalf (Author), Mandy Kwong (Author), Meric Ovacik (Author), Travis W. Bainbridge (Author), Christine Moussion (Author), Gautham K. Rao (Author), Kapil Gadkar (Author), Amrita V. Kamath (Author), Saroja Ramanujan (Author)
• Format: Book
• Published: MDPI AG, 2024-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

FLT3L-Fc is a half-life extended, effectorless Fc-fusion of the native human FLT3-ligand. In cynomolgus monkeys, treatment with FLT3L-Fc leads to a complex pharmacokinetic/pharmacodynamic (PK/PD) relationship, with observed nonlinear PK and expansion of different immune cell types across different d...